This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Monday's Health Winners & Losers

A merger, an FDA holdup and management musical-chairs yanked health care stocks in different directions Monday, resulting in a flat day for the biotech and pharmaceutical indices.

Women's health company Hologic (HOLX - Get Report) announced a $6.2 billion deal to buy Cytyc (CYTC), which manufactures cervical cancer screening equipment. Hologic, which manufactures mammography and breast care products, expects to complete the transaction in the third calendar quarter of 2007. Hologic said the combined companies' annual revenues would be more than $1.7 billion, while adjusted earnings per share would be between $2.35 and $2.40. Hologic's shares fell $3.67, or 6.9%, to $53.94, while Cytyc's shares were up $7.80, or 22%, to $42.85.

Point Therapeutics (POTP), Cleveland BioLabs (CBLI - Get Report) and Nektar Therapeutics (NKTR - Get Report) were affected by differing study results.

Point Therapeutics fell 30 cents, or 69%, to 14 cents, after the Food and Drug Administration placed the clinical program for talabostat on hold. The company recommended stopping two phase III studies as a potential treatment for patients with advanced non-small-cell lung cancer because neither of two endpoints demonstrated improvement over the placebo groups.

Cleveland BioLabs said a study for Protectan CBLB612 showed blood from healthy mice treated with the drug helped mice issued a normally lethal dose of radiation survive past the 60-day mark. The company said the experiment demonstrated effectiveness in stimulation and mobilization of stem cells. Shares rose 37 cents, or 3.4%, to $9.27.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CBLI $3.25 -4.40%
HOLX $33.10 -2.60%
NKTR $10.54 -2.10%
AAPL $131.90 1.20%
FB $82.22 0.85%

Markets

DOW 18,077.27 -2.87 -0.02%
S&P 500 2,114.42 -3.27 -0.15%
NASDAQ 5,070.4750 -21.61 -0.42%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs